Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes.

Who Took Part

The study group was 108 individuals.

PubMed indexes the participants as teenagers and adults.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the individuals nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

Some individuals received a placebo instead of Exenatide, giving a reference point.

The Exenatide group and the comparison group ran side by side rather than switching.

Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.

The primary results of this study, the MAG1C (Meal-time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 108 individuals.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page, all human trials.